Are GLP-1 therapies truly safe for long-term cardiovascular health? Dr Pandey unpacks key gaps in current research, ...
Investor's Business Daily on MSN2h
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...
HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback